Heinz Schmidli
Heinz Schmidli
Statistical Methodology, Novartis, Basel, Switzerland
Verified email at novartis.com
Title
Cited by
Cited by
Year
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts
F Bretz, H Schmidli, F König, A Racine, W Maurer
Biometrical Journal: Journal of Mathematical Methods in Biosciences 48 (4 …, 2006
2512006
Robust meta‐analytic‐predictive priors in clinical trials with historical control information
H Schmidli, S Gsteiger, S Roychoudhury, A O'Hagan, D Spiegelhalter, ...
Biometrics 70 (4), 1023-1032, 2014
1772014
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12‐and 36‐month results
G Levy, H Schmidli, J Punch, E Tuttle‐Newhall, D Mayer, P Neuhaus, ...
Liver transplantation 12 (11), 1640-1648, 2006
1412006
Advantages of Artificial Neural Networks (ANNs) as alternative modelling technique for data sets showing non-linear relationships using data from a galenical study on a solid …
J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger
European Journal of Pharmaceutical Sciences 7 (1), 5-16, 1998
1371998
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice‐daily capsules in Alzheimer's disease patients
G Lefevre, G Sędek, SS Jhee, MT Leibowitz, HL Huang, A Enz, S Maton, ...
Clinical Pharmacology & Therapeutics 83 (1), 106-114, 2008
1362008
Population pharmacokinetics of imatinib mesylate in patients with chronic‐phase chronic myeloid leukaemia: results of a phase III study
H Schmidli, B Peng, GJ Riviere, R Capdeville, M Hensley, I Gathmann, ...
British journal of clinical pharmacology 60 (1), 35-44, 2005
1342005
A faunistic approach to assess potential side-effects of genetically modified Bt-Corn on non-target arthropods under field conditions
MP Candolfi, K Brown, C Grimm, B Reber, H Schmidli
Biocontrol Science and Technology 14 (2), 129-170, 2004
1292004
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations
H Schmidli, F Bretz, A Racine, W Maurer
Biometrical Journal 48 (4), 635-643, 2006
1152006
Everolimus therapeutic concentration range defined from a prospective trial with reduced-exposure cyclosporine in de novo kidney transplantation
JM Kovarik, H Tedesco, J Pascual, G Civati, MN Bizot, J Geissler, ...
Therapeutic drug monitoring 26 (5), 499-505, 2004
1102004
Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure–effect modeling
RC Starling, JM Hare, P Hauptman, KR McCurry, HW Mayer, JM Kovarik, ...
American Journal of Transplantation 4 (12), 2126-2131, 2004
882004
Pharmacokinetics and electrocardiographic pharmacodynamics of artemether‐lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy …
G Lefèvre, P Carpenter, C Souppart, H Schmidli, M McClean, D Stypinski
British journal of clinical pharmacology 54 (5), 485-492, 2002
882002
Rivastigmine exposure provided by a transdermal patch versus capsules
F Mercier, G Lefèvre, HL Aaron Huang, H Schmidli, B Amzal, ...
Current medical research and opinion 23 (12), 3199-3204, 2007
832007
Comparison of artificial neural networks (ANN) with classical modelling techniques using different experimental designs and data from a galenical study on a solid dosage form
J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger
European journal of pharmaceutical sciences 6 (4), 287-300, 1998
831998
Therapeutic drug monitoring for everolimus in kidney transplantation using 12‐month exposure, efficacy, and safety data
MI Lorber, C Ponticelli, J Whelchel, HW Mayer, J Kovarik, Y Li, H Schmidli
Clinical transplantation 19 (2), 145-152, 2005
802005
The Effects of a Flexible Visual Acuity–Driven Ranibizumab Treatment Regimen in Age-Related Macular Degeneration: Outcomes of a Drug and Disease Model
FG Holz, JF Korobelnik, P Lanzetta, P Mitchell, U Schmidt-Erfurth, S Wolf, ...
Investigative ophthalmology & visual science 51 (1), 405-412, 2010
782010
Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development
J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger
Pharmaceutical development and technology 2 (2), 95-109, 1997
781997
Application of artificial neural networks (ANN) in the development of solid dosage forms
J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger
Pharmaceutical development and technology 2 (2), 111-121, 1997
771997
Blinded sample size reestimation with count data: methods and applications in multiple sclerosis
T Friede, H Schmidli
Statistics in Medicine 29 (10), 1145-1156, 2010
562010
Pitfalls of artificial neural networks (ANN) modelling technique for data sets containing outlier measurements using a study on mixture properties of a direct compressed dosage …
J Bourquin, H Schmidli, P van Hoogevest, H Leuenberger
European journal of pharmaceutical sciences 7 (1), 17-28, 1998
531998
Interaction Trial between Artemether‐Lumefantrine (Riamet®) and Quinine in Healthy Subjects
G Lefèvre, P Carpenter, C Souppart, H Schmidli, JM Martin, A Lane, ...
The Journal of Clinical Pharmacology 42 (10), 1147-1158, 2002
522002
The system can't perform the operation now. Try again later.
Articles 1–20